Introduction: Alteplase is widely used as an intravenous thrombolytic drug in acute ischemic stroke (AIS). Recently however, tenecteplase, a modified form of tissue plasminogen activator, has been shown to increase early recanalization rate and proven be non-inferior with similar safety profile compared alteplase. This study aims evaluate the cost-effectiveness 0.25 mg/kg tenecteplase versus 0....

Background: Cardiovascular (CV) diseases remain a leading and costly cause of death globally. Patients with previous CV events are at high risk recurrence. Secondary prevention therapies improve factor control reduce disease costs. Objectives: To assess the cost-effectiveness polypill strategy (CNIC-Polypill) compared loose combination monocomponents to factors in patients coronary heart or str...

CMS operates the quality improvement organization (QIO) program to improve the quality of care delivered to Medicare beneficiaries. Although there have been several studies regarding the effectiveness of this program, there have not been studies regarding this program's value. This article seeks to answer the value question using costutility analysis. Although additional research is warranted, ...

BACKGROUND Studies on the immunotherapy for Alzheimer's disease (AD) have increasingly gained attention since 1990s. However, there are pros (preventing of AD) and cons (incurred cost and side effects) regarding the administration of immunotherapy. Up to date, there has been lacking of economic evaluation for immunotherapy of AD. We aimed to assess the cost-effectiveness analysis of the vaccina...

ObjectivesUncontrolled hypertension is a common cause of cardiovascular disease, which the deadliest and costliest chronic disease in United States. Pharmacists are an accessible community healthcare resource equipped with clinical skills to improve management through medication therapy (MTM). Nevertheless, current reimbursement models do not incentivize pharmacists provide services. We aim inv...

BACKGROUND Clinical studies have demonstrated statistically significant reduction of breast cancer relapse and improved overall survival by adding trastuzumab for 1 year after adjuvant chemotherapy in human epidermal growth factor receptor-2 protein (HER2)/neu-positive breast cancer. The aim of this study was to analyze the cost-effectiveness of HER2/neu testing and the addition of 1-year adjuv...

This study estimates the annual numbers of eight work-related cancers, total losses of quality-adjusted life years (QALYs), and lifetime healthcare expenditures that possibly could be saved by improving occupational health in Taiwan. Three databases were interlinked: the Taiwan Cancer Registry, the National Mortality Registry, and the National Health Insurance Research Database. Annual numbers ...

The half-cycle correction is often used in discrete Markov models to estimate state membership. This article shows that the correction, in addition to being unintuitive, actually produces the wrong results in many circumstances. These include quality-adjusted life year (QALY) weights and unit costs that differ by cycle. The half-cycle correction is also incompatible with discounting of the obta...

Using discrete choice experiments (DCEs) to estimate health state utility values has become an important alternative to the conventional methods of Time Trade-Off and Standard Gamble. Studies using DCEs have typically used the conditional logit to estimate the underlying utility function. The conditional logit is known for several limitations. In this paper, we propose two types of models based...

Harris levels two main criticisms against our original defence of QALYs (Quality Adjusted Life Years). First, he rejects the assumption implicit in the QALY approach that not all lives are of equal value. Second, he rejects our appeal to Rawls's veil of ignorance test in support of the QALY method. In the present article we defend QALYs against Harris's criticisms. We argue that some of the con...